Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma

Affiliations

• ¹ Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY. [email protected].
• ² Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
• ³ Humanitas University and IRCCS Humanitas Research Hospital, Milan.
• ⁴ Hôpital Claude Huriez and CHU de Lille, Lille.
• ⁵ Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, VIC.
• ⁶ CHU de Montpellier, Montpellier.
• ⁷ Allegheny Health Network, Pittsburgh, PA.
• ⁸ Ospedale Santa Maria delle Croci, Ravenna.
• ⁹ Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center (CNIO), Complutense University Madrid, imas12, Madrid.
• ¹⁰ Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
• ¹¹ Hospital del Mar, Passeig Maritim, Barcelona.
• ¹² Tisch Cancer Institute, New York, NY.
• ¹³ University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki.
• ¹⁴ F. Hoffmann-La Roche Ltd, Basel.
• ¹⁵ Roche Products Ltd, Welwyn Garden City.
• ¹⁶ Genentech, Inc., South San Francisco, CA, USA and.
• ¹⁷ Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon.